Histogen Featured on Economic Report Television Series
Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, will be featured in an upcoming segment of The Economic Report as part of the 21st Century Breakthroughs for Biomedical Research series. Phoenix, AZ (PRWEB) December 5, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, will be featured in an upcoming segment of The Economic Report as part of the 21st Century Breakthroughs for Biomedical Research series. Airings of the segment will begin on AZ-TV, local channel 7, on Saturday, December 6th, at 6:00am.
Through Histogen's proprietary bioreactor process which mimics the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families - ExCeltrixTM, Histogen's human Extracellular Matrix (ECM) and ReGenicaTM, Histogen's proprietary liquid complex - which address areas from research tools to tissue repair, skin rejuvenation to hair growth.
The Economic Report segment featuring Histogen focuses on the Company's unique ability to support stem cell research, while developing products that do not contain embryonic stem cells or animal components. In addition, the segment shares the results of Histogen's first clinical evaluation of ReGenica as a post-resurfacing treatment, as well as the potential for a ReGenica formulation in the area of hair regrowth.
For more information about Histogen, or to view the segment online, please visit www.histogeninc.com. Further information about Histogen Aesthetics upcoming line of skin, hair and nail care products can be found at www.histogenaesthetics.com.
###
Simillar Articles
 | | Alberto-Culver Founder Leonard Lavin Joins Histogen Board of Directors |
| Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced that Leonard Lavin, founder and chairman emeritus of the... |
|
| | Histogen Announces Initial Close of Series A Financing Round |
| Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced the initial close of Series A financing at $5.35 million. |
|
| | Histogen Announces Start of Hair Regrowth Clinical Evaluation |
| Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced the start of the Company's first human clinical evaluation of... |
|
| | Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine... |
| ExCeltrix Preliminary Oncology Data Presented for the First Time |
|
| | Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit |
| Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today launched BioNuesisTM, the only soluble human extracellular matrix (ECM)... |
|
|
